Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 3, 2011, Pages 730-743

  Gardner, Ann ^a   Boles, Richard G ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ATP; Inflammation; Major depression; Mitochondrial; MtDNA; Unipolar depression

Indexed keywords

ACETYLCARNITINE; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ASCORBIC ACID; CARNITINE; CLOMIPRAMINE; CREATINE; CYTOKINE; FLUOXETINE; IMIPRAMINE; LITHIUM; MITOCHONDRIAL DNA; MONOAMINE; NORTRIPTYLINE; RIBOFLAVIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THIOCTIC ACID; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UBIQUINONE;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; BIPOLAR DISORDER; COMORBIDITY; DEGENERATIVE DISEASE; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR DEPRESSION; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOOD DISORDER; MUSCLE BIOPSY; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; RISK FACTOR; SHORT SURVEY; SYMPTOMATOLOGY;

ANIMALS; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; INFLAMMATION; MALE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MOOD DISORDERS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; SEROTONIN;

EID: 79954578338     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.030     Document Type: Short Survey

References (232)

1. Akkus S., Naziroglu M., Eris S., Yalman K., Yilmaz N., Yener M. Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia. Cell Biochem Funct 2009, 27(4):181-185.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders (DSM-IV) 1994, American Psychiatric Association, Washington, DC. 4th ed.
3. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010, 67(4):360-368.
4. Angst J. Major depression in 1998: are we providing optimal therapy. J Clin Psychiatry 1999, 60(Suppl 6):5-9.
5. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005, 5(4):525-539.
6. Bachmann R.F., Wang Y., Yuan P., Zhou R., Li X., Alesci S., et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009, 12(6):805-822.
7. Bassit R.A., Curi R., Costa Rosa L.F. Creatine supplementation reduces plasma levels of pro-inflammatory cytokines and PGE2 after a half-ironman competition. Amino Acids 2008, 35(2):425-431.
8. Battisti C., Formichi P., Cardaioli E., Bianchi S., Mangiavacchi P., Tripodi S.A., et al. Cell response to oxidative stress induced apoptosis in patients with Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 2004, 75(12):1731-1736.
9. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res 2010, 176(2-3):183-189.
10. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 2006, 6(11):3414-3425.
11. Belisle S.E., Leka L.S., Delgado-Lista J., Jacques P.F., Ordovas J.M., Meydani S.N. Polymorphisms at cytokine genes may determine the effect of vitamin E on cytokine production in the elderly. J Nutr 2009, 139(10):1855-1860.
12. Bell I.R., Edman J.S., Morrow F.D., Marby D.W., Mirages S., Perrone G., et al. B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc 1991, 39(3):252-257.
13. Bell I.R., Morrow F.D., Read M., Berkes S., Perrone G. Low thyroxine levels in female psychiatric inpatients with riboflavin deficiency: implications for folate-dependent methylation. Acta Psychiatr Scand 1992, 85(5):360-363.
14. Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management. CNS Drugs 2007, 21(9):727-740.
15. Ben-Chetrit E., Peleg H., Aamar S., Heyman S.N. The spectrum of MEFV clinical presentations-is it familial Mediterranean fever only. Rheumatology (Oxf) 2009, 48(11):1455-1459.
16. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 2002, 83(6):1241-1251.
17. Ben-Shachar D., Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE 2008, 3(11):e3676.
18. Bergemann E.R., Boles R.G. Maternal inheritance in recurrent early-onset depression. Psychiatr Genet 2010, 20(1):31-34.
19. Bø S.H., Davidsen E.M., Gulbrandsen P., Dietrichs E., Bovim G., Stovner L.J., et al. Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia 2009, 29(3):365-372.
20. Boehnke C., Reuter U., Flach U., Schuh-Hofer S., Einhäupl K.M., Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004, 11(7):475-477.
21. Boles R.G., Burnett B.B., Gleditsch K., Wong S., Guedalia A., Kaariainen A., et al. A high predisposition to depression and anxiety in mothers and other matrilineal relatives of children with presumed maternally inherited mitochondrial disorders. Am J Med Genet B Neuropsychiatr Genet 2005, 137B(1):20-24.
22. Bosbach S., Kornblum C., Schröder R., Wagner M. Executive and visuospatial deficits in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Brain 2003, 126(Pt 5):1231-1240.
23. Bredesen D.E., Rao R.V., Mehlen P. Cell death in the nervous system. Nature 2006, 443(7113):796-802.
24. Breslau N., Lipton R.B., Stewart W.F., Schultz L.R., Welch K.M. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003, 60(8):1308-1312.
25. Brini M., Pinton P., King M.P., Davidson M., Schon E.A., Rizzuto R. A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat Med 1999, 5(8):951-954.
26. Burgmer M., Gaubitz M., Konrad C., Wrenger M., Hilgart S., Heuft G., et al. Decreased gray matter volumes in the cingulo-frontal cortex and the amygdala in patients with fibromyalgia. Psychosom Med 2009, 71(5):566-573.
27. Búrigo M., Roza C.A., Bassani C., Fagundes D.A., Rezin G.T., Feier G., et al. Effect of electroconvulsive shock on mitochondrial respiratory chain in rat brain. Neurochem Res 2006, 31(11):1375-1379.
28. Burnett B.B., Gardner A., Boles R.G. Mitochondrial inheritance in depression, dysmotility and migraine J Affect Disord 2005, 88(1):109-116.
29. Campbell S., MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 2006, 19(1):25-33.
30. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004, 161(4):598-607.
31. Capuron L., Fornwalt F.B., Knight B.T., Harvey P.D., Ninan P.T., Miller A.H. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals J Affect Disord 2009, 119(1-3):181-185.
32. Capuron L., Moranis A., Combe N., Cousson-Gélie F., Fuchs D., De Smedt-Peyrusse V., et al. Vitamin E status and quality of life in the elderly: influence of inflammatory processes. Br J Nutr 2009, 102(10):1390-1394.
33. Carelli V., Bellan M. Myelin, mitochondria, and autoimmunity: what's the connection. Neurology 2008, 70(13 Pt 2):1075-1076.
34. Cassano G.B., Dell'Osso L., Frank E., Miniati M., Fagiolini A., Shear K., et al. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord 1999, 54(3):319-328.
35. Cataldo A.M., McPhie D.L., Lange N.T., Punzell S., Elmiligy S., Ye N.Z., et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol 2010, 177(2):575-585.
36. Chinnery P.F., Schon E.A. Mitochondria. J Neurol Neurosurg Psychiatry 2003, 74(9):1188-1199.
37. Chinnery P.F., Turnbull D.M. Mitochondrial medicine. QJM 1997, 90(11):657-667.
38. Ciccone D.S., Natelson B.H. Comorbid illness in women with chronic fatigue syndrome: a test of the single syndrome hypothesis. Psychosom Med 2003, 65(2):268-275.
39. Cobianchi L., Fornoni A., Pileggi A., Molano R.D., Sanabria N.Y., Gonzalez-Quintana J., et al. Riboflavin inhibits IL-6 expression and p38 activation in islet cells. Cell Transplant 2008, 17(5):559-566.
40. Condò M., Posar A., Arbizzani A., Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 2009, 10(5):361-365.
41. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967, 113(504):1237-1264.
42. Cordero M.D., Moreno-Fernández A.M., deMiguel M., Bonal P., Campa F., Jiménez-Jiménez L.M., et al. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin Biochem 2009, 42(7-8):732-735.
43. Corruble E., Guelfi J.D. Pain complaints in depressed inpatients. Psychopathology 2000, 33(6):307-309.
44. Curti C., Mingatto F.E., Polizello A.C., Galastri L.O., Uyemura S.A., Santos A.C. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Mol Cell Biochem 1999, 199(1-2):103-109.
45. de Lange F.P., Kalkman J.S., Bleijenberg G., Hagoort P., van der Meer J.W., Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage 2005, 26(3):777-781.
46. Depeint F., Bruce W.R., Shangari N., Mehta R., O'Brien P.J. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact 2006, 163(1-2):94-112.
47. Di Lorenzo C., Pierelli F., Coppola G., Grieco G.S., Rengo C., Ciccolella M., et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 2009, 72(18):1588-1594.
48. Diamond M., Kelly J.P., Connor T.J. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol 2006, 16(7):481-490.
49. DiMauro S., Schon E.A. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008, 31:91-123.
50. DiMauro S., Hirano M., Kaufmann P., Mann J.J. Mitochondrial psychiatry. Mitochondrial medicine 2006, 261-277. Informa Healthcare, London. S. DiMauro, M. Hirano, E.A. Schon (Eds.).
51. Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., O'Brien S., O'Mahony L., et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker. Gastroenterology 2006, 130(2):304-311.
52. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67(5):446-457.
53. Fattal O., Link J., Quinn K., Cohen B.H., Franco K. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007, 12(6):429-438.
54. Feng J., Zhang Z., Li W., Shen X., Song W., Yang C., et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. PLoS ONE 2009, 4(12):e8480.
55. Filosto M., Tomelleri G., Tonin P., Scarpelli M., Vattemi G., Rizzuto N., et al. Neuropathology of mitochondrial diseases. Biosci Rep 2007, 27(1-3):23-30.
56. Finsterer J. Mitochondriopathies. Eur J Neurol 2004, 11(3):163-186.
57. Finsterer J., Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010, 33(2):138-151.
58. Fletcher M.A., Zeng X.R., Barnes Z., Levis S., Klimas N.G. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009, 7:96.
59. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303(1):47-53.
60. Frances A.J., Egger H.L. Whither psychiatric diagnosis. Aust N Z J Psychiatry 1999, 33(2):161-165.
61. Garakani A., Win T., Virk S., Gupta S., Kaplan D., Masand P.S. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003, 10(1):61-67.
62. Gardner A., Boles R.G. Is a "mitochondrial psychiatry" in the futureA review. Curr Psychiatr Rev 2005, 1(3):255-271.
63. Gardner A., Boles R.G. Mitochondrial energy depletion in depression with somatization. Psychother Psychosom 2008, 77(2):127-129.
64. Gardner A., Boles R.G. Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc Med 2008, 22(2):7.
65. Gardner A., Pagani M. A review of SPECT in neuropsychiatric disorders: neurobiological background, methodology, findings and future perspectives. Alasbimn J 2003, 5(21). [http://www2.alasbimnjournal.cl/alasbimn/CDA/sec_b/0,1206,SCID%253D4387,00.html].
66. Gardner A., Pagani M., Wibom R., Nennesmo I., Jacobsson H., Hällström T. Alterations of rCBF and mitochondrial dysfunction in major depressive disorder: a case report. Acta Psychiatr Scand 2003, 107(3):233-239.
67. Gardner A., Johansson A., Wibom R., Nennesmo I., von Döbeln U., Hagenfeldt L., et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord 2003, 76(1-3):55-68.
68. Gardner A., Kaplan B.J., Rucklidge J.J., Jonsson B.H., Humble M.B. The potential of nutritional therapy. Science 2010, 327(5963):268.
69. Gold D.R., Cohen B.H. Treatment of mitochondrial cytopathies. Semin Neurol 2001, 21(3):309-325.
70. Goodman D.W., Thase M.E. Recognizing ADHD in adults with comorbid mood disorders: implications for identification and management. Postgrad Med 2009, 121(5):20-30.
71. Gros D.F., Antony M.M., McCabe R.E., Swinson R.P. Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disord 2009, 23(2):290-296.
72. Gu Y., Wang C., Roifman C.M., Cohen A. Role of MHC class I in immune surveillance of mitochondrial DNA integrity. J Immunol 2003, 170(7):3603-3607.
73. Gupta S., Aggarwal S., See D., Starr A. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 1997, 31(1):149-156.
74. Gür A., Karakoç M., Nas K., Cevik R., Denli A., Saraç J. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002, 29(2):358-361.
75. Haas R.H., Parikh S., Falk M.J., Saneto R.P., Wolf N.I., Darin N., et al. Mitochondrial Medicine Society's Committee on Diagnosis. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008, 94(1):16-37.
76. Härtel C., Strunk T., Bucsky P., Schultz C. Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes. Cytokine 2004, 27(4-5):101-106.
77. Hasselmann O., Blau N., Ramaekers V.T., Quadros E.V., Sequeira J.M., Weissert M. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. Mol Genet Metab 2010, 99(1):58-61.
78. Hershey A.D., Powers S.W., Vockell A.L., Lecates S.L., Ellinor P.L., Segers A., et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007, 47(1):73-80.
79. Hohlfeld R., Kerschensteiner M., Stadelmann C., Lassmann H., Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 2006, 27(Suppl 1):S1-S7.
80. Hokama Y., Campora C.E., Hara C., Kuribayashi T., Le Huynh D., Yabusaki K. Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome. J Clin Lab Anal 2009, 23(4):210-212.
81. Holt I.J., Harding A.E., Morgan-Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988, 331(6158):717-719.
82. Houshmand M., Gardner A., Hällström T., Müntzing K., Oldfors A., Holme E. Different tissue distribution of a mitochondrial DNA duplication and the corresponding deletion in a patient with a mild mitochondrial encephalomyopathy: deletion in muscle, duplication in blood. Neuromuscul Disord 2004, 14(3):195-201.
83. Hsu M.C., Harris R.E., Sundgren P.C., Welsh R.C., Fernandes C.R., Clauw D.J., et al. No consistent difference in gray matter volume between individuals with fibromyalgia and age-matched healthy subjects when controlling for affective disorder. Pain 2009, 143(3):262-267.
84. Huang C.N., Jee S.H., Hwang J.J., Kuo Y.F., Chuang L.M. Autoimmune IDDM in a sporadic MELAS patient with mitochondrial tRNA(Leu(UUR)) mutation. Clin Endocrinol (Oxf) 1998, 49(2):265-270.
85. Hudson G., Chinnery P.F. Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet 2006, 15(Spec No 2):R244-R252.
86. Hudson J.I., Arnold L.M., Keck P.E., Auchenbach M.B., Pope H.G. Family study of fibromyalgia and affective spectrum disorder. Biol Psychiatry 2004, 56(11):884-891.
87. Insel T.R., Wang P.S. The STARD trial: revealing the need for better treatments. Psychiatr Serv 2009, 60(11):1466-1467.
88. Ishikawa S., Mima T., Aoki C., Yoshio-Hoshino N., Adachi Y., Imagawa T., et al. Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann Rheum Dis 2009, 68(2):264-272.
89. Isotani H., Fukumoto Y., Kawamura H., Furukawa K., Ohsawa N., Goto Y., et al. Hypoparathyroidism and insulin-dependent diabetes mellitus in a patient with Kearns-Sayre syndrome harbouring a mitochondrial DNA deletion. Clin Endocrinol (Oxf) 1996, 45(5):637-641.
90. Janowsky D.S. Bipolar disorder- and major depression-relevant abstracts from the 2009 9th World Congress of Biological Psychiatry Meeting. Curr Psychiatry Rep 2009, 11(6):509-511.
91. Jeffree R.L., Wills E.J., Harper C. An unusual myopathy: speckled muscle fibers due to enlarged mitochondria. Muscle Nerve 2007, 36(1):118-122.
92. Jesudason E.P., Masilamoni J.G., Jebaraj C.E., Paul S.F., Jayakumar R. Efficacy of dl-alpha lipoic acid against systemic inflammation-induced mice: antioxidant defense system. Mol Cell Biochem 2008, 313(1-2):113-123.
93. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998, 55(8):694-700.
94. Karry R., Klein E., Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry 2004, 55(7):676-684.
95. Kasahara T., Kubota M., Miyauchi T., Noda Y., Mouri A., Nabeshima T., et al. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry 2006, 11(6):577-593. 523.
96. Kasahara T., Kubota M., Miyauchi T., Ishiwata M., Kato T. A marked effect of electroconvulsive stimulation on behavioral aberration of mice with neuron-specific mitochondrial DNA defects. PLoS ONE 2008, 3(3):e1877.
97. Kato T., Stine O.C., McMahon F.J., Crowe R.R. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. Biol Psychiatry 1997, 42(10):871-875.
98. Kato K., Sullivan P.F., Evengård B., Pedersen N.L. A population-based twin study of functional somatic syndromes. Psychol Med 2009, 39(3):497-505.
99. Katyare S.S., Rajan R.R. Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995, 112(3):353-357.
100. Kendler K.S., Muñoz R.A., Murphy G. The development of the Feighner criteria: a historical perspective. Am J Psychiatry 2010, 167(2):134-142.
101. Kenis G., Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002, 5(4):401-412.
102. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003, 8(6):365-370.
103. Kiliçaslan S.M., Ayvali C., Tastan H. A microscopic study of kidney tissue in Familial Mediterranean Fever patients. Cell Biochem Funct 2007, 25(4):363-367.
104. Kim J.H., Suh S.I., Seol H.Y., Oh K., Seo W.K., Yu S.W., et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia 2008, 28(6):598-604.
105. Kim J., Xu M., Xo R., Mates A., Wilson G.L., Pearsall A.W., et al. Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes. Osteoarthritis Cartilage 2010, 18(3):424-432.
106. Klein D.N. Classification of depressive disorders in the DSM-V: proposal for a two-dimension system. J Abnorm Psychol 2008, 117(3):552-560.
107. Koçer A., Memisogullari R., Domaç F.M., Ilhan A., Koçer E., Okuyucu S., et al. IL-6 levels in migraine patients receiving topiramate. Pain Pract 2009, 9(5):375-379.
108. Kodama K., Suzuki M., Toyosawa T., Araki S. Inhibitory mechanisms of highly purified vitamin B2 on the productions of proinflammatory cytokine and NO in endotoxin-induced shock in mice. Life Sci 2005, 78(2):134-139.
109. Koene S., Kozicz T.L., Rodenburg R.J., Verhaak C.M., de Vries M.C., Wortmann S., et al. Major depression in adolescent children consecutively diagnosed with mitochondrial disorder. J Affect Disord 2009, 114(1-3):327-332.
110. Komulainen T., Hinttala R., Kärppä M., Pajunen L., Finnilä S., Tuominen H., et al. POLG1 p.R722H mutation associated with multiple mtDNA deletions and a neurological phenotype. BMC Neurol 2010, 10:29.
111. Kovács G.G., Höftberger R., Majtényi K., Horváth R., Barsi P., Komoly S., et al. Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain 2005, 128(Pt 1):35-41.
112. Kuchinad A., Schweinhardt P., Seminowicz D.A., Wood P.B., Chizh B.A., Bushnell M.C. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain J Neurosci 2007, 27(15):4004-4007.
113. Kuhlmann T., Goldschmidt T., Antel J., Wegner C., König F., Metz I., et al. Gender differences in the histopathology of MS J Neurol Sci 2009, 286(1-2):86-91.
114. Lange G., Holodny A.I., DeLuca J., Lee H.J., Yan X.H., Steffener J., et al. Quantitative assessment of cerebral ventricular volumes in chronic fatigue syndrome. Appl Neuropsychol 2001, 8(1):23-30.
115. Langhorst J., Junge A., Rueffer A., Wehkamp J., Foell D., Michalsen A., et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009, 104(2):404-410.
116. Le Goff P. Is fibromyalgia a muscle disorder Joint Bone Spine 2006, 73(3):239-242.
117. Lee S., Ng K.L., Tsang A. Prevalence and correlates of depression with atypical symptoms in Hong Kong. Aust N Z J Psychiatry 2009, 43(12):1147-1154.
118. Lerman-Sagie T., Leshinsky-Silver E., Watemberg N., Luckman Y., Lev D. White matter involvement in mitochondrial diseases. Mol Genet Metab 2005, 84(2):127-136.
119. Lestienne P., Ponsot G. Kearns-Sayre syndrome with muscle mitochondrial DNA deletion. Lancet 1988, 1(8590):885.
120. Liebregts T., Adam B., Bredack C., Röth A., Heinzel S., Lester S., et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132(3):913-920.
121. Lindberg G., Törnblom H., Iwarzon M., Nyberg B., Martin J.E., Veress B. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. Gut 2009, 58(8):1084-1090.
122. Lister R.E. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002, 30(2):195-199.
123. Luft R. The development of mitochondrial medicine. Proc Natl Acad Sci USA 1994, 1(19):8731-8738.
124. Luft R., Ikkos D., Palmieri G., Ernster L., Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962, 41:1776-1804.
125. Lutz J., Jäger L., de Quervain D., Krauseneck T., Padberg F., Wichnalek M., et al. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study. Arthritis Rheum 2008, 58(12):3960-3969.
126. MacLennan S.C., Wade F.M., Forrest K.M., Ratanayake P.D., Fagan E., Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 2008, 23(11):1300-1304.
127. Maes M., Bosmans E., Suy E., Vandervorst C., De Jonckheere C., Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990-1991, 24(3):115-120.
128. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995, 20(2):111-116.
129. Maes M., De Vos N., Pioli R., Demedts P., Wauters A., Neels H., et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000, 58(3):241-246.
130. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24(1):27-53.
131. Maes M., Mihaylova I., Kubera M., Uytterhoeven M. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009, 30(4):462-469.
132. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 2009, 30(4):470-476.
133. Magis D., Ambrosini A., Sándor P., Jacquy J., Laloux P., Schoenen J. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 2007, 47(1):52-57.
134. Mak A.D. Prevalence and correlates of bipolar II disorder in major depressive patients at a psychiatric outpatient clinic in Hong Kong. J Affect Disord 2009, 112(1-3):201-205.
135. Makay B., Emiroglu N., Unsal E. Depression and anxiety in children and adolescents with familial Mediterranean fever. Clin Rheumatol 2010, 29(4):375-379.
136. Mancuso M., Orsucci D., Coppedè F., Nesti C., Choub A., Siciliano G. Diagnostic approach to mitochondrial disorders: the need for a reliable biomarker. Curr Mol Med 2009, 9(9):1095-1107.
137. Mao P., Reddy P.H. Is multiple sclerosis a mitochondrial disease. Biochim Biophys Acta 2010, 1802(1):66-79.
138. Mathew R.J., Weinman M.L., Mirabi M. Physical symptoms of depression. Br J Psychiatry 1981, 139:293-296.
139. Maurer I.C., Schippel P., Volz H.P. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 2009, 11(5):515-522.
140. McKenzie M., Liolitsa D., Hanna M.G. Mitochondrial disease: mutations and mechanisms. Neurochem Res 2004, 29(3):589-600.
141. Merikangas K.R., He J.P., Brody D., Fisher P.W., Bourdon K., Koretz D.S. Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics 2010, 125(1):75-81.
142. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008;31(12):2383-90. Comment in: Diabetes Care 2009;32(5):e56; author reply e57.
143. Miguel-Carrasco J.L., Mate A., Monserrat M.T., Arias J.L., Aramburu O., Vázquez C.M. The role of inflammatory markers in the cardioprotective effect of l-carnitine in L-NAME-induced hypertension. Am J Hypertens 2008, 21(11):1231-1237.
144. Miller A.H. Depression and immunity: a role for T cells Brain Behav Immun 2010, 24(1):1-8.
145. Miwa K., Fujita M. Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome. Int J Cardiol 2009, 136(2):238-239.
146. Mizukami K., Sasaki M., Suzuki T., Shiraishi H., Koizumi J., Ohkoshi N., et al. Central nervous system changes in mitochondrial encephalomyopathy: light and electron microscopic study. Acta Neuropathol 1992, 83(4):449-452.
147. Morrissey S.P., Borruat F.X., Miller D.H., Moseley I.F., Sweeney M.G., Govan G.G., et al. Bilateral simultaneous optic neuropathy in adults: clinical, imaging, serological, and genetic studies. J Neurol Neurosurg Psychiatry 1995, 58(1):70-74.
148. Mullick M.S., Nahar J.S., Haq S.A. Psychiatric morbidity, stressors, impact, and burden in juvenile idiopathic arthritis. J Health Popul Nutr 2005, 23(2):142-149.
149. Myhill S., Booth N.E., McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009, 2(1):1-16.
150. Nahon E., Israelson A., Abu-Hamad S., Varda S.B. Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett 2005, 579(22):5105-5110.
151. Nierenberg A.A., Miyahara S., Spencer T., Wisniewski S.R., Otto M.W., Simon N., et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 2005, 57(11):1467-1473.
152. Nordquist N., Oreland L. Serotonin, genetic variability, behaviour, and psychiatric disorders-a review. Ups J Med Sci 2010, 115(1):2-10.
153. Oexle K., Oberle J., Finckh B., Kohlschütter A., Nagy M., Seibel P., et al. Islet cell antibodies in diabetes mellitus associated with a mitochondrial tRNA(Leu(UUR)) gene mutation. Exp Clin Endocrinol Diabetes 1996, 104(3):212-217.
154. Öhman L., Isaksson S., Lindmark A.C., Posserud I., Stotzer P.O., Strid H., et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009, 104(5):1205-1212.
155. Okasha A., Okasha T. Notes on mental disorders in Pharaonic Egypt. Hist Psychiatry 2000, 11:413-424.
156. Oldfors A., Fyhr I.M., Holme E., Larsson N.G., Tulinius M. Neuropathology in Kearns-Sayre syndrome. Acta Neuropathol 1990, 80(5):541-546.
157. Owen A.J., Batterham M.J., Probst Y.C., Grenyer B.F., Tapsell L.C. Low plasma vitamin E levels in major depression: diet or disease Eur J Clin Nutr 2005, 59(2):304-306.
158. Ozawa T. Genetic and functional changes in mitochondria associated with aging. Physiol Rev 1997, 77(2):425-464.
159. Palace J. Inflammation versus neurodegeneration: consequences for treatment. J Neurol Sci 2007, 259(1-2):46-49.
160. Palace J. Multiple sclerosis associated with Leber's hereditary optic neuropathy. J Neurol Sci 2009, 286(1-2):24-27.
161. Parashos I.A., Tupler L.A., Blitchington T., Krishnan K.R. Magnetic-resonance morphometry in patients with major depression. Psychiatry Res 1998, 84(1):7-15.
162. Parikh S., Cohen B.H., Gupta A., Lachhwani D.K., Wyllie E., Kotagal P. Metabolic testing in the pediatric epilepsy unit. Pediatr Neurol 2008, 38(3):191-195.
163. Parikh S., Saneto R., Falk M.J., Anselm I., Cohen B.H., Haas R. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009, 11(6):414-430.
164. Patarca R. Cytokines and chronic fatigue syndrome. Ann NY Acad Sci 2001, 933:185-200.
165. Perez F., Anne O., Debruxelles S., Menegon P., Lambrecq V., Lacombe D., et al. Leber's optic neuropathy associated with disseminated white matter disease: a case report and review. Clin Neurol Neurosurg 2009, 111(1):83-86.
166. Perini F., D'Andrea G., Galloni E., Pignatelli F., Billo G., Alba S., et al. Plasma cytokine levels in migraineurs and controls. Headache 2005, 45(7):926-931.
167. Pettegrew J.W., Levine J., McClure R.J. Acetyl-l-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 2000, 5(6):616-632.
168. Piao Y.S., Tang G.C., Yang H., Lu D.H. Clinico-neuropathological study of a Chinese case of familial adult Leigh syndrome. Neuropathology 2006, 26(3):218-221.
169. Quiroz J.A., Gray N.A., Kato T., Manji H.K. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008, 33(11):2551-2565.
170. Regenold W.T., Phatak P., Marano C.M., Gearhart L., Viens C.H., Hisley K.C. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res 2007, 151(3):179-188. 30.
171. Regenold W.T., Phatak P., Makley M.J., Stone R.D., Kling M.A. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci 2008, 275(1-2):106-112.
172. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007, 35(2):235-242.
173. Roitman S., Green T., Osher Y., Karni N., Levine J. Creatine monohydrate in resistant depression: a preliminary study. Bipolar Disord 2007, 9(7):754-758.
174. Rosenberg R.N. Mitochondrial medicine. Book review. Arch Neurol 2006, 63(10):1505.
175. Rousseau G. Depression's forgotten genealogy: notes towards a history of depression. Hist Psychiatry 2000, 11(41 Pt 1):71-106.
176. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443(7113):780-786.
177. Sabunciyan S., Kirches E., Krause G., Bogerts B., Mawrin C., Llenos I.C., et al. Quantification of total mitochondrial DNA and mitochondrial common deletion in the frontal cortex of patients with schizophrenia and bipolar disorder. J Neural Transm 2007, 114(5):665-674.
178. Sándor P.S., Di Clemente L., Coppola G., Saenger U., Fumal A., Magis D., et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005, 64(4):713-715.
179. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22(2):67-73.
180. Sarchielli P., Alberti A., Baldi A., Coppola F., Rossi C., Pierguidi L., et al. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006, 46(2):200-207.
181. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122(5):509-522.
182. Schmelzer C., Lorenz G., Lindner I., Rimbach G., Niklowitz P., Menke T., et al. Effects of Coenzyme Q10 on TNF-alpha secretion in human and murine monocytic cell lines. Biofactors 2007, 31(1):35-41.
183. Schmelzer C., Lorenz G., Rimbach G., Döring F. Influence of coenzyme Q_{10} on release of pro-inflammatory chemokines in the human monocytic cell line THP-1. Biofactors 2007, 31(3-4):211-217.
184. Schmelzer C., Lindner I., Rimbach G., Niklowitz P., Menke T., Döring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 2008, 32(1-4):179-183.
185. Schmidt-Wilcke T., Luerding R., Weigand T., Jürgens T., Schuierer G., Leinisch E., et al. Striatal grey matter increase in patients suffering from fibromyalgia-a voxel-based morphometry study. Pain 2007, 132(Suppl 1):S109-S116.
186. Schoenen J., Jacquy J., Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998, 50(2):466-470.
187. Scholte H.R., Luyt-Houwen I.E., Vaandrager-Verduin M.H. The role of the carnitine system in myocardial fatty acid oxidation: carnitine deficiency, failing mitochondria and cardiomyopathy. Basic Res Cardiol 1987, 82(Suppl 1):63-73.
188. Schon E.A., Bonilla E., DiMauro S. Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr 1997, 29(2):131-149.
189. Schwartz M., Vissing J. New patterns of inheritance in mitochondrial disease. Biochem Biophys Res Commun 2003, 310(2):247-251.
190. Sciacco M., Prelle A., Comi G.P., Napoli L., Battistel A., Bresolin N., et al. Retrospective study of a large population of patients affected with mitochondrial disorders: clinical, morphological and molecular genetic evaluation. J Neurol 2001, 248(9):778-788.
191. Shao L., Martin M.V., Watson S.J., Schatzberg A., Akil H., Myers R.M., et al. Mitochondrial involvement in psychiatric disorders. Ann Med 2008, 40(4):281-295.
192. Simon G.E., VonKorff M., Piccinelli M., Fullerton C., Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999, 341(18):1329-1335.
193. Smeitink J.A. Mitochondrial disorders: clinical presentation and diagnostic dilemmas. J Inherit Metab Dis 2003, 26(2-3):199-207.
194. Souza M.E., Polizello A.C., Uyemura S.A., Castro-Silva O., Curti C. Effect of fluoxetine on rat liver mitochondria. Biochem Pharmacol 1994, 48(3):535-541. 3.
195. Sparaco M., Bonilla E., DiMauro S., Powers J.M. Neuropathology of mitochondrial encephalomyopathies due to mitochondrial DNA defects. J Neuropathol Exp Neurol 1993, 52(1):1-10.
196. Sparaco M., Simonati A., Cavallaro T., Bartolomei L., Grauso M., Piscioli F., et al. MELAS: clinical phenotype and morphological brain abnormalities. Acta Neuropathol 2003, 106(3):202-212.
197. Sparaco M., Feleppa M., Lipton R.B., Rapoport A.M., Bigal M.E. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 2006, 26(4):361-372.
198. Spinazzola A., Zeviani M. Disorders from perturbations of nuclear-mitochondrial intergenomic cross-talk. J Intern Med 2009, 265(2):174-192.
199. Sprague A.H., Khalil R.A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009, 78(6):539-552.
200. Steiner T.J., Hering R., Couturier E.G., Davies P.T., Whitmarsh T.E. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997, 17(6):673-675.
201. Steingard R.J., Renshaw P.F., Hennen J., Lenox M., Cintron C.B., Young A.D., et al. Smaller frontal lobe white matter volumes in depressed adolescents. Biol Psychiatry 2002, 52(5):413-417.
202. Stine O.C., Luu S.U., Zito M., Casanova M. The possible association between affective disorder and partially deleted mitochondrial DNA. Biol Psychiatry 1993, 33(2):141-142.
203. Stockmeier C.A., Mahajan G.J., Konick L.C., Overholser J.C., Jurjus G.J., Meltzer H.Y., et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004, 56(9):640-650.
204. Su K.G., Banker G., Bourdette D., Forte M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 2009, 9(5):411-417.
205. Sullivan P.F., Kendler K.S. Typology of common psychiatric syndromes. An empirical study. Br J Psychiatry 1998, 173:312-319.
206. Szuster-Ciesielska A., Slotwinska M., Stachura A., Marmurowska-Michalowska H., Dubas-Slemp H., Bojarska-Junak A., et al. Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(3):686-694.
207. Tanahashi C., Nakayama A., Yoshida M., Ito M., Mori N., Hashizume Y. MELAS with the mitochondrial DNA 3243 point mutation: a neuropathological study. Acta Neuropathol 2000, 99(1):31-38.
208. Tarnopolsky M.A. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev 2008, 60(13-14):1561-1567.
209. Thompson L.M. Neurodegeneration: a question of balance. Nature 2008, 452(7188):707-708.
210. Törnblom H., Lindberg G., Nyberg B., Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123(6):1972-1979.
211. Tousoulis D., Drolias A., Antoniades C., Vasiliadou C., Marinou K., Latsios G., et al. Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int J Cardiol 2009, 134(2):238-243.
212. Turconi A.C., Benti R., Castelli E., Pochintesta S., Felisari G., Comi G., et al. Focal cognitive impairment in mitochondrial encephalomyopathies: a neuropsychological and neuroimaging study. J Neurol Sci 1999, 170(1):57-63.
213. Van Alboom E., Louis P., Van Zandijcke M., Crevits L., Vakaet A., Paemeleire K. Diagnostic and therapeutic trajectory of cluster headache patients in Flanders. Acta Neurol Belg 2009, 109(1):10-17.
214. Vasic N., Walter H., Höse A., Wolf R.C. Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: a voxel-based morphometry study. J Affect Disord 2008, 109(1-2):107-116.
215. Veress B., Nyberg B., Törnblom H., Lindberg G. Intestinal lymphocytic epithelioganglionitis: a unique combination of inflammation in bowel dysmotility: a histopathological and immunohistochemical analysis of 28 cases. Histopathology 2009, 54(5):539-549.
216. Vermeulen R.C., Scholte H.R. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med 2004, 66(2):276-282.
217. Vernon S.D., Whistler T., Cameron B., Hickie I.B., Reeves W.C., Lloyd A. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus. BMC Infect Dis 2006, 6:15.
218. Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988, 242(4884):1427-1430.
219. Wallace D.J., Linker-Israeli M., Hallegua D., Silverman S., Silver D., Weisman M.H. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxf) 2001, 40(7):743-749.
220. Weinbach E.C., Costa J.L., Nelson B.D., Claggett C.E., Hundal T., Bradley D., et al. Effects of tricyclic antidepressant drugs on energy-linked reactions in mitochondria. Biochem Pharmacol 1986, 35(9):1445-1451.
221. Whatley S.A., Curti D., Marchbanks R.M. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res 1996, 21(9):995-1004.
222. Wilens T.E., Biederman J., Wozniak J., Gunawardene S., Wong J., Monuteaux M. Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder Findings from a sample of clinically referred adults. Biol Psychiatry 2003, 54(1):1-8.
223. Winokur G. All roads lead to depression: clinically homogeneous, etiologically heterogeneous. J Affect Disord 1997, 45(1-2):97-108.
224. Winokur A., Maislin G., Phillips J.L., Amsterdam J.D. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 1988, 145(3):325-330.
225. Yeretssian G., Labbé K., Saleh M. Molecular regulation of inflammation and cell death. Cytokine 2008, 43(3):380-390.
226. Zeviani M., Moraes C.T., DiMauro S., Nakase H., Bonilla E., Schon E.A., et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988, 38(9):1339-1346.
227. Zhang D.M., Zhou Z.G., Weng J.P., Li L.R., Deng H., Zhang C., et al. Etiological dissection in common anti-islet autoantibody-negative patients with type 1 diabetes [abstract in English]. Zhonghua Yi Xue Za Zhi 2004, 84(15):1247-1251.
228. Zhang Z., Cherryholmes G., Mao A., Marek C., Longmate J., Kalos M., et al. High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med (Maywood) 2008, 233(9):1171-1180.
229. Zhang W.H., Wang H., Wang X., Narayanan M.V., Stavrovskaya I.G., Kristal B.S., et al. Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury. Stroke 2008, 39(2):455-462.
230. Ziaei S., Kazemnejad A., Sedighi A. The effect of vitamin E on the treatment of menstrual migraine. Med Sci Monit 2009, 15(1):CR16-CR19.
231. Zimmerman M., Galione J.N., Chelminski I., McGlinchey J.B., Young D., Dalrymple K., et al. A simpler definition of major depressive disorder. Psychol Med 2010, 40(3):451-457.
232. Zou K., Deng W., Li T., Zhang B., Jiang L., Huang C., et al. Changes of brain morphometry in first-episode, drug-naïve, non-late-life adult patients with major depression: an optimized voxel-based morphometry study. Biol Psychiatry 2010, 67(2):186-188.